- The report contains detailed information about Mayne Pharma Group Limited that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Mayne Pharma Group Limited. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Mayne Pharma Group Limited financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Mayne Pharma Group Limited competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Mayne Pharma Group Limited business.
About Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialist pharmaceutical company, engages in the development, manufacture, and commercialization of oral dosage form drugs. Its principal product includes SUBA Itraconazole capsules for the treatment of fungal infection of nail, finger, or toe. The companys products also comprise various capsules and tablets, including Astrix, a form of aspirin indicated for chronic use in cardiovascular or cerebrovascular disease; Doryx, a delayed release oral formulation used as adjunctive treatment of severe acne; Eryc/Erymax, a delayed release drug used in the treatment of various bacterial infections; Kapanol/Kadian, a sustained release oral formulation used in the management of chronic pain; and Magnoplasm paste for treatment in abscesses, boils, and blind pimples. In addition, its pipeline under various development stages consist of drugs for the treatment of various therapeutic areas, including alimentary, analgesia, anti-fungal, anti-infective, anti-inflammatory, cardiovascular, central nervous, genitourinary, and respiratory. Further, the company offers contract manufacturing services for healthcare, biopharmaceutical, and biotechnology companies. It markets its products in Australia, the United States, Canada, the United Kingdom, Korea, Hong Kong, Singapore, Sri Lanka, and Mauritius. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited on November 19, 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Melbourne, Australia.
RESEARCH METHODOLOGY
DISCLAIMER
1. MAYNE PHARMA GROUP LIMITED COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. MAYNE PHARMA GROUP LIMITED BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. MAYNE PHARMA GROUP LIMITED SWOT ANALYSIS
3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats
4. MAYNE PHARMA GROUP LIMITED FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. MAYNE PHARMA GROUP LIMITED COMPETITORS AND INDUSTRY ANALYSIS
5.1. Mayne Pharma Group Limited Direct Competitors
5.2. Comparison of Mayne Pharma Group Limited and Direct Competitors Financial Ratios
5.3. Comparison of Mayne Pharma Group Limited and Direct Competitors Stock Charts
5.4. Mayne Pharma Group Limited Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Mayne Pharma Group Limited Industry Position Analysis
6. MAYNE PHARMA GROUP LIMITED NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. MAYNE PHARMA GROUP LIMITED EXPERTS REVIEW*
7.1. Experts Opinion
7.2. Experts Estimates
APPENDIX 1: RATIO DEFINITIONS
LIST OF TABLES
Mayne Pharma Group Limited Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Mayne Pharma Group Limited Key Executives
Key Executives Biographies*
Key Executives Compensations*
Mayne Pharma Group Limited Major Shareholders
Mayne Pharma Group Limited History
Mayne Pharma Group Limited Products
Revenues by Product
Revenues by Region
Mayne Pharma Group Limited Offices and Representations
Mayne Pharma Group Limited SWOT Analysis
Income Statement 2009-2012 Including 4-years Trends
Income Statement Latest 4 Quarters Including Trends
Balance Sheet 2009-2012 Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Cash Flow 2009-2012 Including Trends
Cash Flow Latest 4 Quarters Including Trends
Mayne Pharma Group Limited Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Mayne Pharma Group Limited Capital Market Snapshot
Mayne Pharma Group Limited Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Mayne Pharma Group Limited Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Mayne Pharma Group Limited Consensus Recommendations*
Analyst Recommendation Summary*
Price Target Summary*
Experts Recommendation Trends*
Revenue Estimates Analysis*
Earnings Estimates Analysis*
Historical Surprises*
Revenue Estimates Trend*
Earnings Estimates Trend*
Revenue Revisions*
Earnings Revisions*
LIST OF FIGURES
Mayne Pharma Group Limited Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Mayne Pharma Group Limited 1-year Stock Charts
Mayne Pharma Group Limited 5-year Stock Charts
Mayne Pharma Group Limited vs. Main Indexes 1-year Stock Chart
Mayne Pharma Group Limited vs. Direct Competitors 1-year Stock Charts
Mayne Pharma Group Limited Article Density Chart
* – Data availability depends on company’s security policy.
The complete financial data is available for public traded companies.
The above Company Fundamental Report is a half-ready report.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get up-to-date version for the same price.
